From Wikipedia, the free encyclopedia
Chemical compound
FGI-106
|
|
Legal status |
|
---|
|
N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
CompTox Dashboard (
EPA) | |
---|
|
Formula | C28H38N6 |
---|
Molar mass | 458.654 g·mol−1 |
---|
3D model (
JSmol) | |
---|
CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C
|
InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32) Key:WJUPENLNVUCETH-UHFFFAOYSA-N
|
FGI-106 is a broad-spectrum
antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular
viral hemorrhagic fevers from the
bunyavirus,
flavivirus and
filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses
hantavirus,
Rift Valley fever virus and
Crimean-Congo hemorrhagic fever virus, the flavivirus
dengue virus, and the filoviruses
Ebola virus and
Marburg virus.
[1]
[2]
[3]
[4]
[5]
See also
References
-
^ Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, et al. (September 2009). "Development of a broad-spectrum antiviral with activity against Ebola virus". Antiviral Research. 83 (3): 245–51.
doi:
10.1016/j.antiviral.2009.06.001.
PMID
19523489.
-
^ Smith DR, Ogg M, Garrison A, Yunus A, Honko A, Johnson J, Olinger G, Hensley LE, Kinch MS (2010).
"Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae". Virus Adaptation and Treatment: 9.
doi:
10.2147/VAAT.S6903.
-
^ Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, et al. (April 2011).
"Identification of a small-molecule entry inhibitor for filoviruses". Journal of Virology. 85 (7): 3106–19.
doi:
10.1128/JVI.01456-10.
PMC
3067866.
PMID
21270170.
-
^ Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR, Nicastri E (March 2012).
"Viral hemorrhagic fevers: advancing the level of treatment". BMC Medicine. 10: 31.
doi:
10.1186/1741-7015-10-31.
PMC
3325866.
PMID
22458265.
-
^ Picazo E, Giordanetto F (February 2015). "Small molecule inhibitors of ebola virus infection". Drug Discovery Today. 20 (2): 277–86.
doi:
10.1016/j.drudis.2014.12.010.
PMID
25532798.